Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
3 NC counties are under alert, including Johnston County.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arbutus Biopharma Corp
(NQ:
ABUS
)
3.890
+0.080 (+2.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arbutus Biopharma Corp
< Previous
1
2
3
4
Next >
Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts
August 01, 2024
While the Arbutus layoffs represents a major overhaul operationally, the market has responded positively to ABUS stock. Here’s why.
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024
May 02, 2024
ABUS stock results show that Arbutus Biopharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
April 05, 2024
The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood.
Via
InvestorPlace
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
April 04, 2024
Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
April 04, 2024
Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance
May 04, 2023
Via
Benzinga
Recap: Arbutus Biopharma Q1 Earnings
May 04, 2023
Via
Benzinga
Arbutus Biopharma's Earnings Outlook
May 03, 2023
Via
Benzinga
Why Arbutus Biopharma Stock Is Sinking Today
April 25, 2023
After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump.
Via
The Motley Fool
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
April 03, 2024
Arbutus Biopharma soared more than 20% on Wednesday, April 3, after the company received permission to pursue a claim against Moderna in court.
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
October 05, 2023
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Why Arbutus Biopharma Stock Is Plunging Today
April 25, 2023
Via
Benzinga
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
April 12, 2023
Via
Benzinga
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
April 04, 2023
Via
Benzinga
Arbutus Biopharma's Return On Capital Employed Insights
December 12, 2022
Via
Benzinga
Recap: Arbutus Biopharma Q2 Earnings
August 04, 2022
Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Arbutus Biopharma: Q1 Earnings Insights
May 05, 2022
Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
December 06, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
September 13, 2022
Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares!
Via
InvestorPlace
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
August 26, 2022
Moderna Inc (NASDAQ: MRNA) has
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
July 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
July 06, 2022
The company isn't seeking an injunction, but wants "fair compensation."
Via
Investor's Business Daily
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
July 05, 2022
The company isn't seeking an injunction, but wants "fair compensation."
Via
Investor's Business Daily
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
June 28, 2022
Via
Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 9
May 09, 2022
CNBC Ford Motor Selling 8M Shares Of Rivian Automotive
Via
Benzinga
Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ
May 09, 2022
Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking...
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Arbutus Biopharma Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 28, 2022
Arbutus Biopharma (NASDAQ:ABUS) will host a conference call at 08:45 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.